Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 23 December 2021

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 23 December 2021
[Full scale view available at title link above]
[No change from 23 December 2021]

 

::::::

COVID Vaccines/Therapeutics – Developer/Manufacturer Announcements
[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

 

AstraZeneca
Press Releases – No new digest announcements identified

Bharat Biotech
Press Releases – No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias
22 de Enero, 2022
Mambisa: Candidato vacunal anti-covid-19 para administración por vía nasal demuestra seguridad e inmunogenicidad y avanza en ensayos clínicos
[Mambisa: Anti-covid-19 vaccine candidate for nasal administration demonstrates safety and immunogenicity and advances in clinical trials]

19 de Enero, 2022
Avanza investigación con el candidato vacunal Mambisa
BioCubaFarma
[Research advances with the vaccine candidate Mambisa]

19 de Enero, 2022
Más de cuatro millones de cubanos han recibido dosis de refuerzo contra la COVID-19.
BioCubaFarma
[More than four million Cubans have received booster doses against COVID-19.’

 

CanSinoBIO
News – [Website not responding at inquiry]

Clover Biopharmaceuticals – China
News
Clover’s Final SPECTRA Phase 2/3 Clinical Trial Efficacy Data Is Published in The Lancet [COVID-19 vaccine candidate, SCB-2019]
January 20, 2022

 

Curevac [Bayer Ag – Germany]
News
January 17, 2022
CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

 

Janssen/JNJ
Press Releases – No new digest announcements identified

 

Moderna
Press Releases – No new digest announcements identified

 

Novavax
Press Releases
Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine
Jan 19, 2022

 

Pfizer
Recent Press Releases
01.18.2022
Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant
NEW YORK, January 18, 2022 — Pfizer Inc. (NYSE: PFE) today shared results from multiple studies demonstrating that the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), is maintained against the SARS-CoV-2 variant Omicron. Taken together, these in vitro studies suggest that PAXLOVID has the potential to maintain plasma concentrations many-fold times higher than the amount required to prevent Omicron from replicating in cells…

 

Sanofi Pasteur
Press Releases – No new digest announcements identified

 

Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases
Collaboration in Africa, COVID-19 prevention and control working together with SINOVAC
2022/01/20 Event

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media
19 January 2022 Tony Wood appointed Chief Scientific Officer designate, GSK
:: Tony Wood to assume full accountability for GSK R&D in August 2022
:: Hal Barron to transition in August 2022 from CSO to a GSK Non-Executive Director with additional responsibilities to support R&D

 

Merck
News releases
January 18, 2022
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine

 

Novartis
News – No new digest announcements identified

 

SK Biosciences
Press releases
SK bioscience Complete Recruitment for Phase III Clinical Trial of COVID-19 Vaccine
Recruitment of global Phase III clinical trial of ‘GBP510’ completed, with vaccine expected to be au…
2022. 01. 18

 

Valneva
Press Releases
January 19, 2022
Valneva’s Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant
:: Preliminary laboratory studies demonstrate that three doses of Valneva’s inactivated COVID-19 vaccine candidate VLA2001 induced neutralization of the Omicron variant (B.1.1.529 lineage)
:: 100% of tested serum samples presented neutralizing antibodies against the ancestral virus and Delta variant, and 87% against the Omicron variant